What is Design Therapeutics, Inc.'s (DSGN) StockRank?

MoatMap's StockRank for Design Therapeutics, Inc. (DSGN) is 40/100, with a Hold signal. This is a composite score combining Quality (39), Value (37), and Momentum (56) factor ranks across MoatMap's 19,000+ stock universe.

Does Design Therapeutics, Inc. have an economic moat?

Design Therapeutics, Inc. (DSGN) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Design Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Design Therapeutics, Inc. (DSGN) is Hold, based on a StockRank of 40/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Design Therapeutics, Inc. in?

Design Therapeutics, Inc. (DSGN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DSGN

HOLDREMOVE

Design Therapeutics, Inc. · Healthcare · United States · $671M · Avg Vol: $12M/d

StockRank

P/E (TTM)

—

ROE

-31.3%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Design Therapeutics is an early-stage biotechnology company. It does not possess the validated manufacturing scale or pricing power of a high-utilization CDMO, making it a highly speculative binary bet rather than a quality compounder.

COMPANY DESCRIPTION

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene-targeted small molecule therapies for serious degenerative diseases. Its proprietary GeneTAC (Gene-Targeting Chimeric) platform enables the precise modulation of disease-causing RNA and protein, offering a novel therapeutic approach. The company distinguishes itself by pioneering this new class of small molecule drugs, aiming to address the root causes of severe genetic conditions with high unmet medical needs.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-1.14	-1.19	-0.88	-1.22	—
Shares	56M	56M	57M	60M	+8.1%
Debt	4M	3M	2M	2M	-25.4%
Equity	327M	278M	242M	213M	-13.4%
Op CF	-51M	-59M	-43M	-54M	—
Inv CF	-221M	53M	44M	23M	—
Fin CF	235,000	724,000	513,000	26M	—

PRICE (1M)-15.4%

SMA 50SMA 200

$11.14

RSI (14)

45.8

52W High

$17.25

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-37.3%18.5

ROE

-31.3%24.6

GP/Assets

-25.7%3.9

Op. Margin

0.0%40.6

FCF/Assets

-14.0%23.5

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.01x86.6

Current Ratio

22.28x96.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-6.0x75.0

P/FCF

—N/A

P/B

3.1x37.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

65%48.0

RS 6M

12%84.5

SMA 50/200

1.30x94.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-36%10.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$671M

P/E (Forward)

-6.7x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DSGN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DSGN	Design Therapeutics, Inc.(you)	$671M	40	HOLD
0JDK.L	Iovance Biotherapeutics, Inc.	$638M	43	HOLD
ACRS	Aclaris Therapeutics, Inc.	$638M	36	HOLD
GERN	Geron Corporation	$802M	38	HOLD
GYRE	Gyre Therapeutics, Inc.	$557M	38	HOLD
0KCS.L	OPKO Health, Inc.	$734M	44	HOLD
SLDB	Solid Biosciences Inc.	$696M	46	HOLD
ANL	Adlai Nortye Ltd.	$728M	35	SELL
CLYM	Climb Bio, Inc.	$649M	46	HOLD
OVID	Ovid Therapeutics Inc.	$493M	41	HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Design Therapeutics, Inc. (DSGN) — Stock Score Summary

Design Therapeutics, Inc. (DSGN) has a MoatMap StockRank of 40/100 based on Quality (39/100), Value (37/100), and Momentum (56/100) factor scores. The current signal is HOLD. Design Therapeutics is an early-stage biotechnology company. It does not possess the validated manufacturing scale or pricing power of a high-utilization CDMO, making it a highly speculative binary bet rather than a quality compounder.

Key Financial Metrics

Price	$11.14
Market Cap	$671M
P/E (Forward)	-6.71
Price/Book	3.14
Return on Equity	-31.3%
Return on Invested Capital	-37.3%
Debt/Equity	1.25
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-32M

Design Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Design Therapeutics, Inc.’s (DSGN) StockRank?: MoatMap’s StockRank for Design Therapeutics, Inc. (DSGN) is 40/100, with a Hold signal. It is a composite of Quality (39), Value (37), and Momentum (56) factor ranks across MoatMap’s 19,000+ stock universe.
Does Design Therapeutics, Inc. have an economic moat?: Design Therapeutics, Inc. (DSGN) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Design Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Design Therapeutics, Inc. (DSGN) is Hold, based on a StockRank of 40/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Design Therapeutics, Inc. in?: Design Therapeutics, Inc. (DSGN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).